AbbVie (NYSE:ABBV) Stock Price Up 3.4% – Should You Buy?

Shares of AbbVie Inc. (NYSE:ABBV) traded up 3.4% during mid-day trading on Friday . The stock traded as high as $253.35 and last traded at $251.52. 52,480,576 shares were traded during trading, an increase of 636% from the average daily volume of 7,134,102 shares. The stock had previously closed at $243.14.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analysts Set New Price Targets

Several research firms recently commented on ABBV. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AbbVie in a research report on Tuesday. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Finally, Canaccord Genuity Group boosted their price objective on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Trading Up 3.4%

The firm has a market cap of $444.38 billion, a P/E ratio of 123.90, a PEG ratio of 0.72 and a beta of 0.32. The business’s fifty day simple moving average is $214.30 and its 200-day simple moving average is $218.96.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the company earned $2.46 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. As a group, research analysts expect that AbbVie Inc. will post 14.29 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently modified their holdings of the company. Chelsea Counsel Co. bought a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the 4th quarter valued at $28,000. Imprint Wealth LLC grew its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Westend Capital Management LLC purchased a new position in shares of AbbVie during the 4th quarter valued at $29,000. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie in the fourth quarter worth $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.